Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)

NCT04272554 is registered in ClinicalTrials.gov with Spur Therapeutics as lead sponsor.

NCT NCT04272554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04272554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)
Lead sponsor
Spur Therapeutics
Phase
Observational
Overall status
Completed
Start date
February 14, 2020
Completion date
October 10, 2022
Enrollment
37 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

blood coagulation disorder, blood coagulation disorders, inherited, haematologic disease, hemophilia b